(ACHL) Achilles Therapeutics - Ratings and Ratios

Achilles Therapeutics PLC ADR (NASDAQ:ACHL) is a biopharmaceutical company specializing in precision T cell therapies for solid tumors. Their platform focuses on identifying mutations that occur early in cancer development, which are more likely to be present across all tumor cells, making them ideal targets. The company utilizes PELEUS, an AI-driven bioinformatics platform, to identify clonal neoantigens, which are more consistent and thus better targets for therapy. Achilles is developing CHIRON, an autologous T cell therapy in Phase I/IIa trials for advanced non-small cell lung cancer, and THETIS, another autologous T cell therapy in Phase I/IIa trials for metastatic melanoma. These therapies involve extracting a patients T cells, engineering them to target specific neoantigens, and reinfusing them, offering a personalized approach to cancer treatment. While promising, this method is complex and costly, with significant manufacturing challenges. The company, originally named Achilles TX Limited, rebranded in February 2021 and is headquartered in London, UK.

Ticker Symbol: ACHL Exchange: NASDAQ Type: common stock Country Origin: United Kingdom GICS Sub Industry: Biotechnology

Average Volume 20d: 2,491,317 Last Price: 1.39 SMA 20: 1.38 SMA 50: 1.24 SMA 200: 0.99 ATR: 0.04

Market Cap: $58.95M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.55 P/S: 0.00 RoE: -64.84

3-Month Forecast: Based on , ACHLs stock price may remain range-bound between $1.20 and $1.60, with potential volatility near resistance levels. From , the small market cap and negative RoE indicate financial risks, while the P/B ratio suggests undervaluation. Clinical trial progress could act as catalysts, but the companys financial health may impact stock performance.